Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Blood. 2012 Apr 5;119(14):3245-55. doi: 10.1182/blood-2011-08-373738. Epub 2012 Feb 15.
Over the past 10 years, significant progress has been made in understanding HIV-associated lymphomas and improving the prognosis of these diseases. With the advent of combination antiretroviral therapy and the development of novel therapeutic strategies, most patients with HIV-associated lymphomas are cured. The outcome for the majority of patients with HIV-associated diffuse large B-cell lymphoma and Burkitt lymphoma in particular, is excellent, with recent studies supporting the role of rituximab in these diseases. Indeed, in the combination antiretroviral therapy era, the curability of many patients with HIV-associated lymphoma is similar to their HIV-negative counterparts. New treatment frontiers need to focus on improving the outcome for patients with advanced immune suppression and for those with adverse tumor biology, such as the activated B-cell type of diffuse large B-cell lymphoma and the virally driven lymphomas. Future clinical trials need to investigate novel targeted agents alone and in combination with chemotherapy.
在过去的 10 年中，人们在了解 HIV 相关淋巴瘤并改善这些疾病的预后方面取得了重大进展。随着联合抗逆转录病毒疗法的出现和新治疗策略的发展，大多数 HIV 相关淋巴瘤患者已被治愈。特别是对于大多数 HIV 相关弥漫性大 B 细胞淋巴瘤和伯基特淋巴瘤患者来说，其预后极好，最近的研究支持利妥昔单抗在这些疾病中的作用。实际上，在联合抗逆转录病毒疗法时代，许多 HIV 相关淋巴瘤患者的可治愈性与 HIV 阴性患者相似。新的治疗前沿需要集中精力改善免疫抑制严重患者和肿瘤生物学不良患者的预后，如活化 B 细胞型弥漫性大 B 细胞淋巴瘤和病毒驱动的淋巴瘤。未来的临床试验需要单独研究新型靶向药物以及与化疗联合使用。
